Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease - Takeaways - MDSpire

Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease

  • By

  • Stéphane Prange

  • Elise Metereau

  • Hélène Klinger

  • Marine Huddlestone

  • Melinda De Oliveira

  • Sandra Duperrier

  • Pierre Courault

  • Jérôme Redoute

  • Léon Tremblay

  • Véronique Sgambato

  • Sophie Lancelot

  • Stéphane Thobois

  • March 5, 2025

  • 0 min

Share

  • 1

    Impulse control disorders (ICDs) are common in Parkinson's disease, affecting over 45% of patients within five years of diagnosis.

  • 2

    Dopaminergic treatments, particularly dopamine agonists, significantly contribute to the onset and persistence of ICDs in Parkinson's disease.

  • 3

    This study used PET imaging to investigate serotonergic dysfunction in Parkinson's disease patients with ICDs, focusing on specific brain circuits.

  • 4

    PDICD+ patients exhibited greater serotonergic binding in key brain areas, indicating impaired response inhibition related to impulsivity.

  • 5

    Serotonergic dysfunction in Parkinson's disease contributes to ICDs, highlighting the need for targeted therapeutic approaches beyond dopaminergic treatments.

Original Source(s)

Related Content